Compare ACADIA Pharmaceuticals Inc. (ACAD) vs iShares S&P GSCI Commodity-Indexed Trust ETF (GSG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs iShares S&P GSCI Commodity-Indexed Trust ETF — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.99 (market cap $4.49B), while iShares S&P GSCI Commodity-Indexed Trust ETF trades at $30.05. The key difference: ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, iShares S&P GSCI Commodity-Indexed Trust ETF nearer its low. Which is the better fit depends on your goals.
| ACAD | GSG | |
|---|---|---|
Market Cap | $4.49B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $28.06 | $34.77 |
52-Week Low | $20.06 | $22.06 |
Enterprise Value | $3.69B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
GSG trades at $28.89, up 1.83% today, with a bullish technical signal but mixed moving averages and neutral oscillators. Recent news highlights institutional interest, with JPMorgan Chase increasing its stake by 224.3% in Q3 2025 (SEC filing, 2026-04-07). Commodity ETFs like GSG are gaining attention amid inflation fears and supply constraints, as noted by Zacks Investment Research (2026-04-07).
The outlook for GSG is supported by strong commodity market trends and institutional accumulation, but risks include volatility from geopolitical events and inflation shifts. Key support sits at $28, with resistance near $29. Wall Street sentiment is cautiously optimistic due to macroeconomic tailwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About iShares S&P GSCI Commodity-Indexed Trust ETF
GSG is a diversified commodity ETF that tracks the S&P GSCI Total Return Index. It provides exposure to a broad basket of futures, including energy, metals, and agriculture, with a significant weighting toward the energy sector.
Read more on GSG →
